Asceneuron

About Asceneuron

Asceneuron is a company focused on discovering and developing groundbreaking therapeutics for neurodegenerative disorders with high unmet medical needs, including orphan tauopathies, Alzheimer's, and Parkinson's diseases. Their mission is to improve the lives of patients through innovative treatments targeting tau pathology.

Products & Services

Oral Drugs for Neurodegenerative Diseases:Developing oral drugs aimed at treating Alzheimer's, Parkinson's, and orphan tauopathies by blocking tau pathology.

Specialties

Neurodegenerative Disorders Tau Pathology Alzheimer's Disease Parkinson's Disease Orphan Tauopathies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-07-16 FD: 2024-07-16	6 investors

Series C Latest

2024-07-16

$100.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Abbas Hussain

Chair of the Board of Directors of Asceneuron

Recent News

Asceneuron Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised